| Bid | 4.85 |
| Market Cap | 3.51M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 77.26 |
| PE Ratio (ttm) | 0.06 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 5 |
| Volume | 7,227 |
| Avg. Volume (20D) | 88,011 |
| Open | 4.80 |
| Previous Close | 4.74 |
| Day's Range | 4.68 - 5.00 |
| 52-Week Range | 4.09 - 29.00 |
| Beta | undefined |
About RSLS
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investi...
Analyst Forecast
According to 1 analyst ratings, the average rating for RSLS stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
2 months ago · seekingalpha.com
ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call TranscriptReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas St...